Literature DB >> 32461749

Ceftaroline Cerebrospinal Fluid Penetration in the Treatment of a Ventriculopleural Shunt Infection: A Case Report.

Jeffrey J Cies, Wayne S Moore, Adela Enache, Arun Chopra.   

Abstract

Pharmacokinetic data regarding ceftaroline fosamil (CPT) penetration into cerebrospinal fluid (CSF) are limited to a rabbit model (15% inflamed) and adult case reports. We describe serum and CSF CPT concentrations in a 21-year-old, 34.8 kg female, medically complex patient presented with a 4-day history of fevers (Tmax 39.2°C), tachypnea, tachycardia, fatigue, and a 1-week history of pus and blood draining from the ventriculopleural (VPL) shunt. A head CT and an ultrasound of the neck revealed septated complex fluid collection surrounding the shunt. Therapy was initiated with vancomycin and ceftriaxone. Blood and CSF cultures from hospital day (HD) 1 were positive for methicillin-resistant Staphylococcus aureus with a CPT MIC of 0.5 mg/L and a vancomycin MIC range of 0.5 to 1 mg/L. On HD 3, CPT was added. On HD 7, simultaneous serum (69.4, 44, and 30.2 mg/L) and CSF (1.7, 2.3, and 2.3 mg/L) concentrations were obtained at 0.25, 1.5, and 4.75 hours from the end of an infusion. Based on these concentrations, CPT CSF penetration ratio ranged from 2.4% to 7.6%. After addition of CPT, the blood and CSF cultures remained negative on a regimen of vancomycin plus CPT. On HD 14, a new left-sided VPL shunt was placed. The patient continued on CPT for a period of 7 days after the new VPL shunt placement. This case demonstrated CPT CSF penetration in a range of 2.4% to 7.6%, approximately half of the rabbit model. This allowed for CSF concentrations at least 50% free time > 4 to 6× MIC of the dosing interval with a dosing regimen of 600 mg IV every 8 hours in a 34.8 kg chronic patient and resulted in a successful clinical outcome with no identified adverse outcomes. Copyright Pediatric Pharmacy Association. All rights reserved. For permissions, email: mhelms@pediatricpharmacy.org 2020.

Entities:  

Keywords:  CSF penetration; MRSA; case report; ceftaroline CSF concentrations; ceftaroline fosamil; pediatric; pharmacodynamics; pharmacokinetic

Year:  2020        PMID: 32461749      PMCID: PMC7243901          DOI: 10.5863/1551-6776-25.4.336

Source DB:  PubMed          Journal:  J Pediatr Pharmacol Ther        ISSN: 1551-6776


  27 in total

Review 1.  Ceftaroline for meticillin-resistant Staphylococcus aureus bacteraemia: case series and review of the literature.

Authors:  Hari M Polenakovik; Craig M Pleiman
Journal:  Int J Antimicrob Agents       Date:  2013-08-11       Impact factor: 5.283

2.  Practice guidelines for the management of bacterial meningitis.

Authors:  Allan R Tunkel; Barry J Hartman; Sheldon L Kaplan; Bruce A Kaufman; Karen L Roos; W Michael Scheld; Richard J Whitley
Journal:  Clin Infect Dis       Date:  2004-10-06       Impact factor: 9.079

3.  Ceftaroline CSF concentrations in a patient with ventriculoperitoneal shunt-related meningitis.

Authors:  Safia S Kuriakose; Mohamed Rabbat; Jason C Gallagher
Journal:  J Antimicrob Chemother       Date:  2014-11-23       Impact factor: 5.790

4.  Microbiology and treatment of cerebrospinal fluid shunt infections in children.

Authors:  Daniel J Adams; Michael Rajnik
Journal:  Curr Infect Dis Rep       Date:  2014-10       Impact factor: 3.725

5.  A pharmacokinetic/pharmacodynamic analysis of ceftaroline prophylaxis in patients with external ventricular drains.

Authors:  Gary E Stein; Fadi Yasin; Curtis Smith; Amy Scharmen; Daniel Havlichek; Charles Bill
Journal:  Surg Infect (Larchmt)       Date:  2015-03-31       Impact factor: 2.150

6.  Prospective randomized study of therapy in cerebrospinal fluid shunt infection.

Authors:  H E James; J W Walsh; H D Wilson; J D Connor; J R Bean; P A Tibbs
Journal:  Neurosurgery       Date:  1980-11       Impact factor: 4.654

7.  Lack of benefit of endoscopic ventriculoperitoneal shunt insertion: a multicenter randomized trial.

Authors:  John R W Kestle; James M Drake; D Douglas Cochrane; Ruth Milner; Marion L Walker; Rick Abbott; Frederick A Boop
Journal:  J Neurosurg       Date:  2003-02       Impact factor: 5.115

8.  Examining the use of ceftaroline in the treatment of Streptococcus pneumoniae meningitis with reference to human cathelicidin LL-37.

Authors:  George Sakoulas; Poochit Nonejuie; Ravina Kullar; Joseph Pogliano; Michael J Rybak; Victor Nizet
Journal:  Antimicrob Agents Chemother       Date:  2015-01-20       Impact factor: 5.191

9.  Ceftaroline for Suspected or Confirmed Invasive Methicillin-Resistant Staphylococcus aureus: A Pharmacokinetic Case Series.

Authors:  Jeffrey J Cies; Wayne S Moore; Adela Enache; Arun Chopra
Journal:  Pediatr Crit Care Med       Date:  2018-06       Impact factor: 3.624

10.  Ceftaroline activity tested against bacterial isolates from pediatric patients: results from the assessing worldwide antimicrobial resistance and evaluation program for the United States (2011-2012).

Authors:  Helio S Sader; Rodrigo E Mendes; David J Farrell; Robert K Flamm; Ronald N Jones
Journal:  Pediatr Infect Dis J       Date:  2014-08       Impact factor: 2.129

View more
  2 in total

1.  Population Pharmacokinetic Modeling and Probability of Target Attainment of Ceftaroline in Brain and Soft Tissues.

Authors:  Victória Etges Helfer; Alexandre Prehn Zavascki; Markus Zeitlinger; Bibiana Verlindo de Araújo; Teresa Dalla Costa
Journal:  Antimicrob Agents Chemother       Date:  2022-08-25       Impact factor: 5.938

Review 2.  Ceftaroline Fosamil for Treatment of Pediatric Complicated Skin and Soft Tissue Infections and Community-Acquired Pneumonia.

Authors:  Susanna Esposito; Timothy J Carrothers; Todd Riccobene; Gregory G Stone; Michal Kantecki
Journal:  Paediatr Drugs       Date:  2021-08-31       Impact factor: 3.022

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.